Youngeun Cho, MD
Pain Medicine · Seattle, WANPI 1346583820
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,055 of the $2,500 with a category attached, or 82.2%. 17 manufacturers reported payments, led by Abbott at 37.5% of the total. Reporting peaked in 2022 at $598 and has fallen 94.4% since, to $33 in 2025.
Across 90 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$937
- VGI Medical, LLC$445
- AbbVie$354
- Nalu Medical, Inc.$180
- Boston Scientific$136
- Stimwave Technologies Incorporated$93
- plus $354 from 11 others
What the payments were for
- Food & beverage$2,05582%
- Entertainment$44518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 50 | $937 |
| VGI Medical, LLC | 1 | $445 |
| AbbVie(2 entities) | 17 | $354 |
| Nalu Medical, Inc. | 2 | $180 |
| Boston Scientific | 2 | $136 |
| Stimwave Technologies Incorporated | 2 | $93 |
| Collegium Pharmaceutical, Inc. | 4 | $75 |
| Averitas Pharma Inc. | 1 | $72 |
| GRT US Holding, Inc. | 2 | $39 |
| Pfizer | 2 | $36 |
| Medtronic | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Amgen | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Si-bone, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,500 in reported general payments places this provider in the 55th percentile of 124 pain medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 126 | $3,452 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 68 | $2,521 |
| Oxycodone Hcl | 124 | $2,332 |
| Tizanidine Hcl | 105 | $2,110 |
| Gabapentin | 101 | $1,352 |
| Pregabalin | 42 | $845 |
| Morphine Sulfate | 26 | $799 |
| Fentanyl | 12 | $675 |
| Morphine Sulfate ErMorphine Sulfate | 27 | $629 |
| Buprenorphine Hcl | 15 | $628 |
| Baclofen | 24 | $460 |
| Methadone Hcl | 24 | $419 |
| Duloxetine Hcl | 28 | $404 |
| Zolmitriptan | 13 | $290 |
| Methocarbamol | 21 | $263 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Seattle
- Steven StanosSeattle$206K
- Corrie AndersonSeattle$102K
- Gregory TermanSeattle$95K
- Miroslav BackonjaSeattle$22K
- Alex CahanaSeattle$12K
- Michael GofeldSeattle$8K
- Christopher MerifieldSeattle$5K
- Agnes StogiczaSeattle$5K
- Rana Al-JumahSeattle$4K
- Alexander NguyenSeattle$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.